Search

Search Constraints

You searched for: ISSN 0278-0232

Search Results

42. A PHASE 1 STUDY OF BET INHIBITION USING RG6146 IN RELAPSED/REFRACTORY (R/R) MYC‐EXPRESSING DIFFUSE LARGE B CELL LYMPHOMA (DLBCL). (June 2017)

43. A PHASE 1 STUDY OF PRALATREXATE PLUS ROMIDEPSIN REVEALS MARKED ACTIVITY IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) PERIPHERAL T‐CELL LYMPHOMA (PTCL). (June 2017)

44. A phase 1 study of ruxolitinib, steroids and lenalidomide for relapsed/refractory multiple myeloma patients. Issue 5 (14th August 2022)

46. A phase 1 study to evaluate the feasibility and efficacy of the addition of ropeginterferon alpha‐2b to imatinib treatment in patients with chronic phase chronic myeloid leukemia (CML) not achieving a deep molecular response (molecular remission 4.5)—AGMT_CML 1. Issue 5 (19th August 2020)

47. A PHASE 1/1B DOSE‐ESCALATION TRIAL EVALUATING CPI‐818, AN ORAL INTERLEUKIN‐2‐INDUCIBLE T‐CELL KINASE INHIBITOR, IN PATIENTS WITH RELAPSED/REFRACTORY T‐CELL LYMPHOMA. (12th June 2019)

48. A PHASE 1/2 STUDY OF BRENTUXIMAB VEDOTIN IN PEDIATRIC PATIENTS WITH RELAPSED/REFRACTORY (R/R) SYSTEMIC ANAPLASTIC LARGE‐CELL LYMPHOMA (SALCL) OR R/R HODGKIN LYMPHOMA (HL). (June 2017)

50. A PHASE 1/2 STUDY OF PIXANTRONE, ETOPOSIDE, BENDAMUSTINE AND, IN CD20+ TUMORS, RITUXIMAB IN PATIENTS WITH RELAPSED AGGRESSIVE B‐ OR T‐CELL LYMPHOMAS—THE P[R]EBEN STUDY. (June 2017)